O	0	10	Prevention
O	11	13	of
B-condition	14	20	palmar
I-condition	20	21	-
I-condition	21	28	plantar
I-condition	29	47	erythrodysesthesia
O	48	52	with
O	53	55	an
B-intervention	56	70	antiperspirant
O	71	73	in
B-eligibility	74	80	breast
I-eligibility	81	87	cancer
I-eligibility	88	96	patients
I-eligibility	97	104	treated
I-eligibility	105	109	with
I-eligibility	110	119	pegylated
I-eligibility	120	129	liposomal
I-eligibility	130	141	doxorubicin
O	142	143	(
O	143	147	SAKK
O	148	150	92
O	150	151	/
O	151	153	08
O	153	154	)
O	154	155	.

O	156	164	Elevated
O	165	179	concentrations
O	180	182	of
O	183	194	doxorubicin
O	195	198	are
O	199	204	found
O	205	207	in
O	208	215	eccrine
O	216	221	sweat
O	222	228	glands
O	229	231	of
O	232	235	the
O	236	241	palms
O	242	245	and
O	246	251	soles
O	251	252	.

O	253	255	We
O	256	265	therefore
O	266	275	evaluated
O	276	278	an
O	279	293	antiperspirant
O	294	296	as
O	297	307	preventive
O	308	317	treatment
O	318	321	for
O	322	328	palmar
O	328	329	-
O	329	336	plantar
O	337	355	erythrodysesthesia
O	356	357	(
O	357	361	hand
O	361	362	-
O	362	366	foot
O	367	375	syndrome
O	375	376	)
O	377	379	in
O	380	388	patients
O	389	393	with
O	394	404	metastatic
O	405	411	breast
O	412	418	cancer
O	419	426	treated
O	427	431	with
O	432	441	pegylated
O	442	451	liposomal
O	452	463	doxorubicin
O	463	464	.

O	465	467	An
O	468	482	antiperspirant
O	483	493	containing
O	494	502	aluminum
O	503	516	chlorohydrate
O	517	519	or
B-control	520	527	placebo
I-control	528	533	cream
O	534	537	was
O	538	545	applied
O	546	548	to
O	549	552	the
O	553	557	left
O	558	560	or
O	561	566	right
O	567	571	hand
O	572	575	and
O	576	580	foot
O	581	583	in
O	584	585	a
O	586	592	double
O	592	593	-
O	593	600	blinded
O	601	607	manner
O	608	609	(
O	609	614	intra
O	614	615	-
O	615	622	patient
O	623	636	randomization
O	636	637	)
O	637	638	.

O	639	642	The
O	643	650	primary
O	651	659	endpoint
O	660	663	was
O	664	667	the
B-outcome-Measure	668	672	rate
I-outcome-Measure	673	675	of
I-outcome-Measure	676	681	grade
I-outcome-Measure	682	683	2
I-outcome-Measure	684	686	or
I-outcome-Measure	687	688	3
I-outcome-Measure	689	695	palmar
I-outcome-Measure	695	696	-
I-outcome-Measure	696	703	plantar
I-outcome-Measure	704	722	erythrodysesthesia
O	722	723	.

O	724	725	A
O	726	735	secondary
O	736	744	endpoint
O	745	748	was
O	749	752	the
B-outcome-Measure	753	760	patient
I-outcome-Measure	760	761	-
I-outcome-Measure	761	769	reported
I-outcome-Measure	770	777	symptom
I-outcome-Measure	778	784	burden
I-outcome-Measure	785	786	(
I-outcome-Measure	786	794	tingling
I-outcome-Measure	794	795	,
I-outcome-Measure	796	804	numbness
I-outcome-Measure	804	805	,
I-outcome-Measure	806	810	pain
I-outcome-Measure	810	811	,
I-outcome-Measure	812	814	or
I-outcome-Measure	815	819	skin
I-outcome-Measure	820	828	problems
I-outcome-Measure	828	829	)
O	829	830	.

O	831	836	Using
O	837	844	McNemar
O	844	845	'
O	845	846	s
O	847	854	matched
O	855	860	pairs
O	861	867	design
O	867	868	,
B-total-participants	869	871	53
O	872	880	patients
O	881	885	were
O	886	892	needed
O	893	895	to
O	896	902	detect
O	903	904	a
O	905	907	20
O	907	908	%
O	909	919	difference
O	920	927	between
O	928	931	the
O	932	941	treatment
O	942	945	and
O	946	953	placebo
O	954	959	sides
O	960	964	with
O	965	966	a
O	967	979	significance
O	980	985	level
O	986	988	of
O	989	990	5
O	990	991	%
O	992	995	and
O	996	1001	power
O	1002	1004	of
O	1005	1007	90
O	1007	1008	%
O	1008	1009	.

B-outcome	1010	1015	Grade
I-outcome	1016	1017	2
I-outcome	1018	1020	or
I-outcome	1021	1022	3
I-outcome	1023	1026	PPE
O	1027	1035	occurred
O	1036	1038	in
O	1039	1041	30
O	1042	1043	(
O	1043	1045	58
O	1045	1046	%
O	1046	1047	)
O	1048	1050	of
B-total-participants	1051	1053	52
O	1054	1063	evaluable
O	1064	1072	patients
O	1072	1073	;
O	1074	1076	in
B-cv-bin-abs	1077	1080	six
O	1081	1089	patients
B-outcome	1090	1097	adverse
I-outcome	1098	1105	effects
O	1106	1114	occurred
O	1115	1117	on
O	1118	1121	the
O	1122	1129	placebo
O	1130	1134	side
O	1135	1138	but
O	1139	1142	not
O	1143	1145	on
O	1146	1149	the
O	1150	1159	treatment
O	1160	1164	side
O	1164	1165	,
O	1166	1173	whereas
B-iv-bin-abs	1174	1177	one
O	1178	1185	patient
O	1186	1195	developed
B-outcome	1196	1202	palmar
I-outcome	1202	1203	-
I-outcome	1203	1210	plantar
I-outcome	1211	1229	erythrodysesthesia
O	1230	1232	on
O	1233	1236	the
O	1237	1246	treatment
O	1247	1251	side
O	1252	1256	only
O	1257	1258	(
O	1258	1259	P
O	1260	1261	=
O	1262	1263	0
O	1263	1264	.
O	1264	1266	07
O	1266	1267	)
O	1267	1268	.

B-cv-bin-abs	1269	1273	Four
O	1274	1282	patients
O	1283	1292	developed
B-outcome	1293	1298	grade
I-outcome	1299	1300	2
I-outcome	1301	1303	or
I-outcome	1304	1305	3
I-outcome	1306	1312	palmar
I-outcome	1312	1313	-
I-outcome	1313	1320	plantar
I-outcome	1321	1339	erythrodysesthesia
I-outcome	1340	1342	on
I-outcome	1343	1348	their
I-outcome	1349	1353	foot
O	1354	1356	on
O	1357	1360	the
O	1361	1368	placebo
O	1369	1373	side
O	1374	1377	but
O	1378	1381	not
O	1382	1384	on
O	1385	1388	the
O	1389	1398	treatment
O	1399	1403	side
O	1404	1405	(
O	1405	1406	P
O	1407	1408	=
O	1409	1410	0
O	1410	1411	.
O	1411	1413	05
O	1413	1414	)
O	1414	1415	.

O	1416	1418	In
O	1419	1422	the
O	1423	1429	cohort
O	1430	1434	with
O	1435	1440	grade
O	1441	1442	2
O	1443	1445	or
O	1446	1447	3
O	1448	1454	palmar
O	1454	1455	-
O	1455	1462	plantar
O	1463	1481	erythrodysesthesia
O	1482	1487	there
O	1488	1491	was
O	1492	1493	a
O	1494	1499	trend
O	1500	1507	towards
O	1508	1513	fewer
O	1514	1526	dermatologic
O	1527	1543	symptomatologies
O	1544	1548	with
O	1549	1552	the
O	1553	1559	active
O	1560	1569	treatment
O	1570	1571	(
O	1571	1572	P
O	1573	1574	=
O	1575	1576	0
O	1576	1577	.
O	1577	1579	05
O	1579	1580	)
O	1580	1581	,
O	1582	1585	and
O	1586	1588	no
O	1589	1599	difference
O	1600	1603	for
O	1604	1609	other
O	1610	1617	adverse
O	1618	1624	events
O	1624	1625	.

O	1626	1631	Using
O	1632	1639	topical
O	1640	1648	aluminum
O	1649	1662	chlorohydrate
O	1663	1665	as
O	1666	1668	an
O	1669	1683	antiperspirant
O	1684	1691	appears
O	1692	1694	to
O	1695	1701	reduce
O	1702	1705	the
O	1706	1715	incidence
O	1716	1718	of
O	1719	1724	grade
O	1725	1726	2
O	1727	1729	or
O	1730	1731	3
O	1732	1738	palmar
O	1738	1739	-
O	1739	1746	plantar
O	1747	1765	erythrodysesthesia
O	1766	1775	following
O	1776	1785	pegylated
O	1786	1795	liposomal
O	1796	1807	doxorubicin
O	1808	1820	chemotherapy
O	1821	1824	for
O	1825	1835	metastatic
O	1836	1842	breast
O	1843	1849	cancer
O	1849	1850	.
